Skyrizi is not a steroid. It is a biologic medication, specifically a monoclonal antibody, which is an entirely different class of drug. Steroids and biologics differ in their chemical structure, how they work in the body, how they’re taken, and what side effects they carry. If you’ve been prescribed Skyrizi or are considering it, understanding this distinction matters because it affects what you can expect from treatment.
What Skyrizi Actually Is
Skyrizi (risankizumab) is a lab-engineered protein designed to target one specific part of the immune system. It belongs to a class of medications called monoclonal antibodies, which are large, complex proteins that lock onto a precise molecular target the way a key fits a lock. Steroids, by contrast, are small chemical compounds (either synthetic or based on hormones your body naturally produces) that broadly dial down immune activity and inflammation across multiple systems at once.
The difference is a bit like using a sniper rifle versus a shotgun. Skyrizi zeroes in on a single immune signaling molecule called IL-23. This molecule drives the production of inflammatory cells responsible for conditions like psoriasis and Crohn’s disease. By blocking IL-23 specifically, Skyrizi interrupts the chain of inflammation at its source without suppressing the rest of your immune system the way steroids do.
Why the Confusion With Steroids
The mix-up is understandable. Skyrizi treats many of the same conditions that corticosteroids treat: plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. If you’ve dealt with any of these, there’s a good chance steroids like prednisone were part of your treatment at some point. Both drugs reduce inflammation, so it’s natural to wonder if they’re related.
They aren’t. Corticosteroids work by broadly suppressing your immune response across the board. That wide reach is why they’re effective quickly but also why they cause a long list of side effects when used for extended periods: weight gain, mood changes, sleep disruption, bone thinning (osteoporosis), elevated blood sugar, and increased infection risk. These problems are so well-documented that corticosteroids are not recommended as long-term maintenance therapy for inflammatory bowel disease.
Skyrizi was developed in part to help patients avoid exactly those steroid-related consequences. Research published in the Journal of Crohn’s & Colitis specifically describes risankizumab as a “corticosteroid-sparing therapy,” meaning it can take over the job of controlling inflammation so patients can taper off steroids.
How Skyrizi Works Differently
Your immune system uses signaling molecules called interleukins to coordinate inflammatory responses. In diseases like psoriasis, one of these signals, IL-23, gets stuck in the “on” position. IL-23 drives the production of immune cells that churn out inflammatory chemicals, which in psoriasis cause skin cells to multiply too fast, forming thick, scaly plaques. In Crohn’s disease and ulcerative colitis, the same IL-23 pathway fuels chronic intestinal inflammation and tissue damage.
Skyrizi binds to a specific part of the IL-23 molecule (the p19 subunit) and neutralizes it. With IL-23 blocked, the downstream inflammatory cascade slows dramatically. The rest of your immune defenses, the parts that fight infections and perform everyday surveillance, remain largely intact. This targeted approach is fundamentally different from the broad immunosuppression steroids cause.
What Treatment Looks Like
The way you take Skyrizi also sets it apart from steroids. For psoriasis and psoriatic arthritis, Skyrizi is a subcutaneous injection (under the skin) given at the start of treatment, again four weeks later, and then once every 12 weeks. That’s roughly four or five injections per year after the initial doses. Many patients self-inject at home using a prefilled pen.
For Crohn’s disease and ulcerative colitis, treatment starts with three intravenous infusions given at a clinic (at weeks 0, 4, and 8), then switches to self-administered injections every 8 weeks for ongoing maintenance.
Compare that to corticosteroids, which typically require daily pills or topical applications, sometimes multiple times a day. The infrequent dosing schedule of Skyrizi reflects its long-lasting mechanism: the antibody stays active in your body for weeks, continuously blocking IL-23.
Effectiveness for Psoriasis
Skyrizi’s clinical trial results are notably strong. In the UltIMMA trials, about 75% of patients with moderate-to-severe plaque psoriasis achieved 90% skin clearance by week 16. By week 52, that number climbed to around 81%, and more than half of patients reached completely clear skin. These results outperformed both placebo and two other well-established biologics tested head-to-head.
Steroids can also clear psoriasis quickly, but the improvement tends to be temporary. Psoriasis commonly rebounds, sometimes worse than before, when steroids are stopped. Skyrizi is designed for sustained, long-term control rather than short bursts of relief.
Side Effects Compared to Steroids
Because Skyrizi doesn’t carry the hormonal and metabolic baggage of corticosteroids, you won’t see the classic steroid side effects: moon face, weight gain, thinning skin, elevated blood sugar, or weakened bones. The most common side effects of Skyrizi are upper respiratory infections (like colds), headache, fatigue, and injection-site reactions.
Long-term safety data spanning over six years of continuous use show that serious safety events remained low or decreased over time. Rates of serious infections held steady at about 1.1 events per 100 patient-years, which is consistent with what’s seen in the broader psoriasis population regardless of treatment. Rates of malignancies were similarly in line with background rates for people with psoriasis, with no evidence of immune-suppression-related cancers increasing over the study period.
This long-term profile is one of the key practical differences. Steroids become riskier the longer you take them. Skyrizi, based on available data, does not show that pattern of accumulating harm.
FDA-Approved Uses
Skyrizi is currently approved to treat four conditions:
- Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- Active psoriatic arthritis in adults
- Moderately to severely active Crohn’s disease in adults
- Moderately to severely active ulcerative colitis in adults
In all four conditions, Skyrizi serves as a long-term maintenance option, filling the role that steroids cannot safely occupy for extended periods. For many patients, it represents a way to stay in remission without the ongoing toll that chronic steroid use takes on the body.